Short interest for iBio gives investors a sense of the degree to which investors are betting on the decline of iBio's stock. Short interest data is updated every two weeks.

iBio Stock (AMEX:IBIO), Short Interest Report

iBio

iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: Biopharmaceuticals and Bioprocessing activities, conducted within iBio, Inc. and CDMO segment, conducted within iBio CDMO.

Doctor,Measuring,Obese,Man,Waist,Body,Fat.,Obesity,And,Weight

Biotech

News

Health Care

Contracts

Movers

General

IBIO

iBio surged after collaborating with AstralBio Inc. to develop antibodies for obesity &amp; cardiometabolic conditions. Shares soared over 100%, hitting $2.44. Collaboration aims to target TGFb superfamily for muscle wasting &amp; obesity treatment.

Micro-Cap Stock iBio Doubles On Wednesday - Here&#39;s Why

Long Ideas

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

ALVR

ALPS ETF Trusthen & Steers Global Realty Majors ETF

VYNE

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That May Rocket Higher In Q1

Earnings

Eurozone

Commodities

Small Cap

Global

Intraday Update

CMND

REPL

TVTX

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday.

The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&amp;P 500 also fell, dropping, 0.07% to 4,566.73.

Crude Oil Moves Lower; AutoZone Profit Tops Views

iBio Inc

Offerings

iBio Files Prospectus Relates To Resale From Time To Time Of Up To 10.6M Shares Of Common Stock By Selling Stockholders

<h3>Gainers</h3>
<ul>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 205.16% to $1.95. The market value of their outstanding shares is at $53.6 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares moved upwards by 78.11% to $1.53. The market value of their outstanding shares is at $6.5 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares moved upwards by 50.45% to $0.25. The company's market cap stands at $2.1 million. </li>
<li>iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) shares moved upwards by 27.98% to $4.3. The market value of their outstanding shares is at $14.9 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares rose 27.5% to $4.45. The company's market cap stands at $451.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 21.9% to $0.24 during Friday's pre-market session. The company's market cap stands at $12.6 million. </li>
<li>PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) stock fell 10.26% to $2.45. The company's market cap stands at $19.7 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares declined by 8.62% to $0.38. The market value of their outstanding shares is at $9.9 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) shares decreased by 8.3% to $0.34. The market value of their outstanding shares is at $4.1 million. </li>
<li>LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock declined by 8.21% to $20.02. The company's market cap stands at $511.1 million. </li>
<li>Nautilus Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAUT#NASDAQ">NAUT</a>) shares fell 7.59% to $2.56. The company's market cap stands at $320.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

AVTX

BCDA

BDRX

LENZ

MESO

NAUT

NCNA

PAVM

YTEN

12 Health Care Stocks Moving In Friday's Pre-Market Session

iBio Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NYSE">IBIO</a>) shares are surging after the company entered into a collaboration agreement with&nbsp;AstralBio Inc.&nbsp;on Wednesday to discover, engineer, and develop antibodies to treat obesity and&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37953815/ibio-and-astralbio-announce-transformative-ai-drug-discovery-collaboration-to-rapidly-develop-nove" rel="noreferrer noopener">other cardiometabolic conditions</a>.
The shares are trading over 100% with a strong session volume of 38.98 million compared to an average volume of average Volume 106.958K as per data from&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
This micro-cap biotech player is valued at $4 million, with an enterprise value of $17.7 million.
Tuesday, iBio&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=VWqAuWHsbf4qyXl8rzvujAopwBR5KiSlh_LLBysPX1mcmPMn4TfmtBNqWj6u5poldRH_UDrgaKyswkfYky-rXFNgCo2HyR_bvb2UGESTZt6zgajcgsj-rWKk5KQalNKB2lN2MoRkEzVaJjRgjA1x4Aw9myOuLhltEQZXfCG4R6loE8CRtDGNm5dGosBphtSGbVnv18XfCksYNmkjvTX62g==" rel="noreferrer noopener">announced</a>&nbsp;the closing of a $15 million private placement financing with ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital, and other institutional investors.&nbsp;
The company will use some of the net proceeds to support new partnerships, such as this collaboration with AstralBio.
As part of the collaboration, iBio has granted an exclusive license to its AI-powered technology to identify and engineer four targets for cardiometabolic disease, of which AstralBio may continue the pre-clinical development and deploy its proven drug development expertise to advance candidates to an Investigational New Drug (IND) application.&nbsp;
iBio has the exclusive option to license three cardiometabolic targets from AstralBio and will receive the rights to develop, manufacture and commercialize those targets upon exercise.&nbsp;
As a result of this collaboration, iBio and AstralBio have agreed to initiate the development of a lead program focused on targeting the transforming growth factor beta (TGFb) superfamily for the treatment of muscle wasting and obesity.&nbsp;
Upon mutual consent, the parties may expand the collaboration to include additional targets in other fields.
&#8220;We are confident our AI-enabled technology is exceptionally well positioned to develop antibodies against challenging targets in the cardiometabolic space,&#8221; said iBio&#8217;s CEO and Chief Scientific Officer, Martin Brenner.
Price Action: IBIO shares are up 147.80% at $2.84 on the last check Wednesday.
Photo via Shutterstock

Micro-Cap Stock iBio Doubles On Wednesday - Here's Why

IBIO: 119% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37954771">IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for obesity and cardiometabolic diseases.</a>
DRCT: -49% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37954575">Direct Digital Holdings shares are trading lower after the company reported worse-than-expected Q4 financial results.</a>
NVCR: 42% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37954533">Novocure shares are trading higher after the company&#39;s METIS Phase 3 trial met primary endpoint, demonstrating statistically significant extension in time to intracranial progression for brain metastases from non-small cell lung cancer.</a>

DRCT

NVCR

Market-Moving News for March 27th

WIIM

IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for obesity and cardiometabolic diseases.

iBio, Inc. (NYSEA:IBIO) (&quot;iBio&quot; or the &quot;Company&quot;) announces today that it has entered into a collaboration agreement with AstralBio, Inc. (&quot;AstralBio&quot;) to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions.
Yesterday, iBio&nbsp;<a href="https://www.globenewswire.com/Tracker?data=VWqAuWHsbf4qyXl8rzvujAopwBR5KiSlh_LLBysPX1mcmPMn4TfmtBNqWj6u5poldRH_UDrgaKyswkfYky-rXFNgCo2HyR_bvb2UGESTZt6zgajcgsj-rWKk5KQalNKB2lN2MoRkEzVaJjRgjA1x4Aw9myOuLhltEQZXfCG4R6loE8CRtDGNm5dGosBphtSGbVnv18XfCksYNmkjvTX62g==" target="_blank">announced</a>&nbsp;the closing of a&nbsp;$15 million&nbsp;private placement financing with ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital and other institutional investors. The company will use a portion of the net proceeds to support new partnerships, such as this collaboration with AstralBio.

iBio and AstralBio Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

iBio, Inc.&nbsp; an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into a securities purchase agreement for a private investment in public equity (&quot;PIPE&quot;) financing that is expected to result in gross proceeds to the Company of approximately $15.0 million, before deducting placement agent fees and offering expenses.
Pursuant to the terms of the securities purchase agreement, the Company is selling an aggregate of 5,287,278 shares of common stock (or pre-funded warrant in lieu thereof) and common warrants to purchase up to 5,287,278 shares of common stock at a purchase price of&nbsp;$2.85&nbsp;per share (or pre-funded warrant in lieu thereof), subject to certain beneficial ownership limitations set by each holder.
&ndash; Purchase price of&nbsp;$2.85&nbsp;represents a premium of 148+% to last close &ndash;

Reported Earlier, iBio Raises $15M In Equity Financing, Shares Set At $2.85 Each

Otsuka Pharmaceutical Acquired iBio's Assets Related To Its Early-stage Programmed Cell Death Protein 1 Agonist Program; iBio Will Receive An Upfront Payment Of $1M And Is Eligible To Receive Additional Contingent Cash Payments Of Up To $52.5M

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3>iBio, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ibio#NYSE">IBIO</a>)</h3>
<ul>
<li>On Dec. 5, iBio announced pricing of a $4.5 million public offering. The company&rsquo;s stock fell around 11% over the past five days and has a <a href="https://www.benzinga.com/quote/IBIO">52-week low of $1.16 </a>.</li>
<li>RSI Value: 23.25</li>
<li>IBIO Price Action: Shares of iBio fell 4.9% to close at $1.17 on Friday.</li>
</ul>
<h3>GRI Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gri#NASDAQ">GRI</a>)</h3>
<ul>
<li>On Dec. 5, the company announced the initiation of patient enrollment in the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF. The company&rsquo;s stock fell around 23% over the past month. It <a href="https://www.benzinga.com/quote/GRI"> has a 52-week low </a> of $0.2838.</li>
<li>RSI Value: 27.58</li>
<li>GRI Price Action: Shares of GRI Bio fell 3% to close at $0.3152 on Friday.</li>
</ul>
<h3>AlloVir, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alvr#NASDAQ">ALVR</a>)</h3>
<ul>
<li>On Jan. 1, 2024, AlloVir board approved a reduction its workforce by approximately 95% of current employee base to reduce costs and preserve capital. The company&rsquo;s stock fell around 69% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/ALVR"> low of $0.6230.</a></li>
<li>RSI Value: 28.16</li>
<li>ALVR Price Action: Shares of AlloVir gained 5.3% to close at $0.6950 on Friday.</li>
</ul>
<h3>VYNE Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vyne#NASDAQ">VYNE</a>)</h3>
<ul>
<li>On Nov. 13, VYNE Therapeutics posted a narrower-than-expected quarterly loss. &ldquo;We have made substantial progress in advancing our business in recent months,&rdquo; said David Domzalski, President and Chief Executive Officer of VYNE. &ldquo;With positive results from our Phase 1b trial, we believe there is strong support to advance VYN201 as a potential category-leading therapy in the treatment of vitiligo.&rdquo; The company&rsquo;s shares lost around 24% over the past month. The company&rsquo;s 52-week low is $2.00.</li>
<li>RSI Value: 28.98</li>
<li>VYNE Price Action: Shares of VYNE Therapeutics fell 2.8% to close at $2.06 on Friday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/24/01/36609836/beat-inflation-with-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-streets-mo"> Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street&#39;s Most Accurate Analysts </a>

iBio's Subsidiary, iBio CDMO And Woodforest National Bank Have Amended The Credit Agreement Dated November 1, 2021, Extending The Maturity Date From December 31, 2023 To The Earlier March 29, 2024, Or The Acceleration Of Maturity Of The Term Loan Followin

iBio's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NYSE">IBIO</a>) short percent of float has risen 118.62% since its last report. The company recently reported that it has 880 thousand shares sold short, which is 3.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>iBio Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2023/1702044919_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for iBio has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing iBio's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, iBio's peer group average for short interest as a percentage of float is 1.40%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into iBio's Recent Short Interest

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday.
The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&amp;P 500 also fell, dropping, 0.07% to 4,566.73.
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/12/36086901/dave-busters-gears-up-for-q3-print-heres-a-look-at-recent-price-target-changes-by-the-most-accurate"> Dave &amp; Buster&#39;s Gears Up For Q3 Print; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Information technology shares rose by 0.4% on Tuesday.
In trading on Tuesday, materials shares dipped by 1.3%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
AutoZone Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/azo#NYSE">AZO</a>) reported better-than-expected earnings for its first quarter on Tuesday.
The company posted quarterly sales growth of 5.1% Y/Y to $4.19 billion, marginally missing the analyst consensus of $4.198 billion. EPS of $32.55 beat the consensus of $31.57.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmnd#NASDAQ">CMND</a>) shares shot up 59% to $6.08 after the company announced results in its cocaine addiction treatment.
Shares of Travere Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tvtx#NASDAQ">TVTX</a>) got a boost, shooting 21% to $7.63 after the company announced the completion of a successful pre-NDA meeting with the FDA for FILSPARI in IgA nephropathy and provided regulatory updates for both IgAN and FSGS.
Mercurity Fintech Holding Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mfh#NASDAQ">MFH</a>) shares were also up, gaining 32% to $1.5599. The company announced a $6 million private placement financing.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Replimune Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/repl#NASDAQ">REPL</a>) shares dropped 43% to $7.05 after the company announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for the treatment of locally advanced or metastatic CSCC and provided initial data for all patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial.
Shares of iBio, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ibio#NYSE">IBIO</a>) were down 43% to $1.53 after the company announced pricing of a $4.5 million public offering.
Designer Brands Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dbi#NYSE">DBI</a>) was down, falling 32% to $8.65 after the company reported worse-than-expected third-quarter financial results and lowered FY23 adjusted EPS guidance.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36088456/top-5-tech-stocks-that-could-lead-to-your-biggest-gains-in-december"> Top 5 Tech Stocks That Could Lead To Your Biggest Gains In December</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.8% to $72.48 while gold traded down 0.3% at $2,035.90.
Silver traded down 1.7% to $24.475 on Tuesday while copper fell 1.3% to $3.7860.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares closed mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.40%, London&rsquo;s FTSE 100 fell 0.31% while Spain&rsquo;s IBEX 35 Index rose 0.59% The German DAX rose 0.78% French CAC 40 rose 0.74%, while Italy&rsquo;s FTSE MIB Index rose 0.56%.
Industrial producer prices in the Eurozone fell by 9.4% year-over-year in October versus a 12.4% decline a month ago. The HCOB Eurozone services PMI was revised higher to 48.7 in November compared to a preliminary level of 48.2, and versus 47.8 in October.
The S&amp;P Global/CIPS UK services PMI was rose to 50.9 in November versus a preliminary reading of 50.5, while French services PMI came at 45.4 in November versus preliminary estimates of 45.3. German services PMI was revised higher to 49.6 in November versus a preliminary reading of 48.7.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly lower on Tuesday, with Japan&rsquo;s Nikkei 225 falling 1.37%, Hong Kong&rsquo;s Hang Seng Index falling 1.91% and China&rsquo;s Shanghai Composite Index falling 1.67%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, climbed 0.63%.
The S&amp;P Global India services PMI fell to 56.9 in November compared to prior month&rsquo;s reading of 58.4, while Caixin China General service PMI rose to 51.5 in November versus 50.4 a month ago. The au Jibun Bank Japan services PMI was revised lower to 50.8 in November compared to a preliminary reading of 51.7, while S&amp;P Global Hong Kong SAR PMI climbed to 50.1 in November compared to 48.9 a month ago. The Reserve Bank of Australia held its cash rates at 4.35% during its recent meeting.
&nbsp;
<h3>Economics</h3>
&nbsp;
The number of job openings fell by 617,000 from the prior month to 8.733 million for October, down from market estimates of 9.3 million.
The S&amp;P Global composite PMI came in at 50.7 in November, unchanged from the prior month&#39;s reading.
The ISM Services PMI rose to 52.7 in November from 51.8 in the previous month and topping market estimates of 52.
The RealClearMarkets/TIPP Economic Optimism Index fell to 40.0 in December from 44.5 a month ago.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36088343/block-to-rally-around-54-here-are-10-top-analyst-forecasts-for-tuesday"> Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Tuesday</a>

Shares of Daktronics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dakt#NASDAQ">DAKT</a>) moved lower during Tuesday&rsquo;s session following <a href="https://www.benzinga.com/quote/DAKT/earnings">weak quarterly results</a>.
Daktronics posted quarterly earnings of 5 cents per share, missing market estimates of 13 cents per share. The company&rsquo;s quarterly sales came in at $199.37 million versus expectations of $213.70 million, according to <a href="http://pro.benzinga.com/">Benzinga Pro</a>.
Daktronics shares declined 10.7% to $9.15 on Tuesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Meiwu Technology Company Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wnw#NASDAQ">WNW</a>) shares climbed 80.6% to $0.13.</li>
<li>Volato Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/soar#NYSE">SOAR</a>) shares gained 72% to $15.13.</li>
<li>Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmnd#NASDAQ">CMND</a>) jumped 62.6% to $6.23 after the company announced results in its cocaine addiction treatment.</li>
<li>Allarity Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allr#NASDAQ">ALLR</a>) climbed 46.9% to $0.8946 after the company announced initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of stenoparib in women with advanced ovarian cancer.</li>
<li>Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) gained 30% to $0.0361 after gaining 29% on Monday. NXU named Sarah Wyant as interim CFO, succeeding Apoorv Dwivedi.</li>
<li>XBP Europe Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xbp#NASDAQ">XBP</a>) surged 24.7% to $47.40.</li>
<li>Travere Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tvtx#NASDAQ">TVTX</a>) gained 24% to $7.80. Travere completed&nbsp;successful pre-NDA meeting for FILSPARI in IgAN. Citigroup upgraded Travere Therapeutics from Neutral to Buy and raised the price target from $7 to $10.</li>
<li>Harbor Custom Development, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcdi#NASDAQ">HCDI</a>) climbed 19.4% to $1.29.</li>
<li>Mercurity Fintech Holding Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mfh#NASDAQ">MFH</a>) surged 17% to $1.3806. Mercurity Fintech announced a $6 million private placement financing.</li>
<li>Heart Test Laboratories, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hscs#NASDAQ">HSCS</a>) jumped 15.7% to $0.2179. HeartSciences received FDA confirmation to change clearance pathway for MyoVista wavECG device and associated AI-ECG algorithm to a 510(k) submission from a De Novo process.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) gained 15.5% to $18.56.</li>
<li>Acrivon Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acrv#NASDAQ">ACRV</a>) climbed 13.2% to $5.93.</li>
<li>MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) gained 12% to $3.7600.</li>
<li>EyePoint Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eypt#NASDAQ">EYPT</a>) rose 8.3% to $19.86.</li>
<li>GitLab Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gtlb#NASDAQ">GTLB</a>) rose 6.8% to $56.55 after the company posted better-than-expected results for its third quarter and issued a strong forecast for FY24.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Replimune Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/repl#NASDAQ">REPL</a>) shares fell 48.1% to $6.39 after the company announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for the treatment of locally advanced or metastatic CSCC and provided initial data for all patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial.</li>
<li>iBio, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ibio#NYSE">IBIO</a>) dipped 42.1% to $1.5625 after the company announced pricing of a $4.5 million public offering.</li>
<li>Designer Brands Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dbi#NYSE">DBI</a>) fell 31.2% to $8.81 after the company reported worse-than-expected third-quarter financial results and lowered FY23 adjusted EPS guidance.</li>
<li>U Power Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ucar#NASDAQ">UCAR</a>) declined 26.9% to $0.4999. U Power recently announced pricing of its registered follow-on offering.</li>
<li>SilverSun Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssnt#NASDAQ">SSNT</a>) shares fell 24.7% to $9.40 after jumping 240% on Monday. SilverSun Technologies announced Jacobs Private Equity II and minority co-investors will invest $1 billion in the company.</li>
<li>NeuroSense Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrsn#NASDAQ">NRSN</a>) fell 24.2% to $1.1293. NeuroSense said it met its primary safety and tolerability &amp; secondary clinical efficacy endpoints in its Phase 2b PARADIGM trial of PrimeC in ALS.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) shares fell 23.7% to $0.6799 after the company reported third-quarter earnings.</li>
<li>Mainz Biomed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>) dipped 23% to $1.2250. Mainz Biomed reported topline results from U.S. eAArly DETECT study evaluating novel mRNA biomarkers.</li>
<li>GRI Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gri#NASDAQ">GRI</a>) shares fell 19.1% to $0.5968. GRI Bio commenced patient enrollment in Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of idiopathic pulmonary fibrosis.</li>
<li>Seelos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/seel#NASDAQ">SEEL</a>) declined 18.4% to $1.60.</li>
<li>America&#39;s Car-Mart, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crmt#NASDAQ">CRMT</a>) fell 18% to $66.31 after the company reported second-quarter financial results.</li>
<li>Alterity Therapeutics Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athe#NASDAQ">ATHE</a>) dipped 14.8% to $3.58. Alterity Therapeutics will host webcast to discuss ATH434 efficacy data in primates and recent clinical progress on Tuesday, Dec. 5 in the US.</li>
<li>Sphere Entertainment Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sphr#NYSE">SPHR</a>) declined 13.5% to $29.07. Sphere Entertainment announced a private offering of $225 million of convertible senior notes.</li>
<li>Genelux Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnlx#NASDAQ">GNLX</a>) fell 12.8% to $11.85.</li>
<li>Evolent Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) fell 10.8% to $26.15 after the company announced a proposed offering of $350M of convertible senior notes due 2029.</li>
<li>Worthington Steel, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ws#NYSE">WS</a>) declined 9.6% to $21.82.</li>
<li>Farfetch Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftch#NASDAQ">FTCH</a>) fell 9.6% to $1.1650.</li>
<li>ArcBest Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arcb#NASDAQ">ARCB</a>) dipped 9.4% to $113.14.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrpx#NASDAQ">VRPX</a>) fell 8.5% to $0.4150 after surging 12% on Monday. Virpax Pharmaceuticals recently appointed Gerald Bruce as CEO and Eric Floyd as Chairman.</li>
<li>Merit Medical Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mmsi#NASDAQ">MMSI</a>) shares fell 8.3% to $67.79 after the company reported a proposed private placement of $550 million of convertible senior notes.</li>
<li>GameStop Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gme#NYSE">GME</a>) fell 8.2% to $15.60.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/12/36093122/ethereum-falls-but-remains-above-this-key-level-ftx-token-gnosis-among-top-losers"> Ethereum Falls But Remains Above This Key Level; FTX Token, Gnosis Among Top Losers</a>

ACRV

ALLR

ARCB

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CRMT

DAKT

EYPT

FTCH

GNLX

GTLB

GYRE

HCDI

HSCS

JOAN

LIFW

MMSI

MYNZ

NRSN

SEEL

SOAR

SPHR

SSNT

UCAR

VRPX

Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>PHAXIAM Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHXM#NASDAQ">PHXM</a>) shares moved upwards by 22.1% to $5.13 during Tuesday's regular session. The market value of their outstanding shares is at $31.1 million. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) stock moved upwards by 20.66% to $7.59. The market value of their outstanding shares is at $570.3 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) stock rose 18.99% to $4.0. The market value of their outstanding shares is at $57.2 million. </li>
<li>Xenetic Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) stock rose 17.84% to $4.16. The company's market cap stands at $6.4 million. </li>
<li>Cerevel Therapeutics Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>) shares moved upwards by 16.28% to $36.98. The company's market cap stands at $6.6 billion. </li>
<li>Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) shares increased by 15.92% to $7.52. The market value of their outstanding shares is at $20.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares decreased by 44.5% to $6.83 during Tuesday's regular session. The company's market cap stands at $403.5 million. </li>
<li>iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) stock declined by 43.66% to $1.52. The market value of their outstanding shares is at $2.1 million. </li>
<li>Seelos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) stock decreased by 25.26% to $1.47. The market value of their outstanding shares is at $10.7 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock fell 25.16% to $1.19. The market value of their outstanding shares is at $24.2 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock fell 23.35% to $0.57. The company's market cap stands at $1.8 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock declined by 16.45% to $0.33. The market value of their outstanding shares is at $16.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCLI

CERE

KALA

PHXM

XBIO

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday.
The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&amp;P 500 also fell, dropping,&nbsp;0.03% to 4,568.46.
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/12/36086901/dave-busters-gears-up-for-q3-print-heres-a-look-at-recent-price-target-changes-by-the-most-accurate"> Dave &amp; Buster&#39;s Gears Up For Q3 Print; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Consumer discretionary shares rose by 0.7% on Tuesday.
In trading on Tuesday, materials shares dipped by 1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
The ISM services PMI rose to 52.7 in November from 51.8 in the previous month and topping market estimates of 52.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmnd#NASDAQ">CMND</a>) shares shot up 49% to $5.72 after the company announced results in its cocaine addiction treatment.
Shares of Allarity Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allr#NASDAQ">ALLR</a>) got a boost, shooting 12% to $0.6850 after the company announced initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of stenoparib in women with advanced ovarian cancer.
Mercurity Fintech Holding Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mfh#NASDAQ">MFH</a>) shares were also up, gaining 30% to $1.53. The company announced a $6 million private placement financing.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Replimune Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/repl#NASDAQ">REPL</a>) shares dropped 48% to $6.40 after the company announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for the treatment of locally advanced or metastatic CSCC and provided initial data for all patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial.
Shares of iBio, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ibio#NYSE">IBIO</a>) were down 41% to $1.5887 after the company announced pricing of a $4.5 million public offering.
Designer Brands Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dbi#NYSE">DBI</a>) was down, falling 32% to $8.72 after the company reported worse-than-expected third-quarter financial results and lowered FY23 adjusted EPS guidance.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36088456/top-5-tech-stocks-that-could-lead-to-your-biggest-gains-in-december"> Top 5 Tech Stocks That Could Lead To Your Biggest Gains In December</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.9% to $73.72 while gold traded up 0.1% at $2,043.60.
Silver traded down 0.6% to $24.77 on Tuesday while copper fell 0.8% to $3.8055.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.35%, London&rsquo;s FTSE 100 fell 0.32% while Spain&rsquo;s IBEX 35 Index rose 0.68% The German DAX rose 0.71% French CAC 40 rose 0.66%, while Italy&rsquo;s FTSE MIB Index rose 0.50%.
Industrial producer prices in the Eurozone fell by 9.4% year-over-year in October versus a 12.4% decline a month ago. The HCOB Eurozone services PMI was revised higher to 48.7 in November compared to a preliminary level of 48.2, and versus 47.8 in October.
The S&amp;P Global/CIPS UK services PMI was rose to 50.9 in November versus a preliminary reading of 50.5, while French services PMI came at 45.4 in November versus preliminary estimates of 45.3. German services PMI was revised higher to 49.6 in November versus a preliminary reading of 48.7.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly lower on Tuesday, with Japan&rsquo;s Nikkei 225 falling 1.37%, Hong Kong&rsquo;s Hang Seng Index falling 1.91% and China&rsquo;s Shanghai Composite Index falling 1.67%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, climbed 0.63%.
The S&amp;P Global India services PMI fell to 56.9 in November compared to prior month&rsquo;s reading of 58.4, while Caixin China General service PMI rose to 51.5 in November versus 50.4 a month ago. The au Jibun Bank Japan services PMI was revised lower to 50.8 in November compared to a preliminary reading of 51.7, while S&amp;P Global Hong Kong SAR PMI climbed to 50.1 in November compared to 48.9 a month ago. The Reserve Bank of Australia held its cash rates at 4.35% during its recent meeting.
&nbsp;
<h3>Economics</h3>
&nbsp;
The number of job openings fell by 617,000 from the prior month to 8.733 million for October, down from market estimates of 9.3 million.
The S&amp;P Global composite PMI came in at 50.7 in November, unchanged from the prior month&#39;s reading.
The ISM Services PMI rose to 52.7 in November from 51.8 in the previous month and topping market estimates of 52.
The RealClearMarkets/TIPP Economic Optimism Index fell to 40.0 in December from 44.5 a month ago.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36088343/block-to-rally-around-54-here-are-10-top-analyst-forecasts-for-tuesday"> Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Tuesday</a>

Dow Falls 100 Points; ISM Services PMI Increases In November

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.23% to 36,120.88 while the NASDAQ fell 0.40% to 14,129.09. The S&amp;P 500 also fell, dropping, 0.30% to 4,556.06.
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/12/36086901/dave-busters-gears-up-for-q3-print-heres-a-look-at-recent-price-target-changes-by-the-most-accurate"> Dave &amp; Buster&#39;s Gears Up For Q3 Print; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Consumer staples shares fell by just 0.05% on Tuesday.
In trading on Tuesday, financial shares dipped by 0.6%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
J.M. Smucker Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sjm#NYSE">SJM</a>) reported better-than-expected earnings for its second quarter on Tuesday.
The company posted a second-quarter FY24 sales decline of 12% year-on-year to $1.94 billion, missing the analyst consensus of $1.95 billion. Adjusted EPS of $2.59 beat the consensus estimate of $2.47.
J.M. Smucker revised FY24 adjusted EPS guidance to $9.25 - $9.65 (prior $9.45 - $9.85) versus the consensus of $9.48.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Volato Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/soar#NYSE">SOAR</a>) shares shot up 72% to $15.13.
Shares of Allarity Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allr#NASDAQ">ALLR</a>) got a boost, shooting 67% to $1.0199 after the company announced initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of stenoparib in women with advanced ovarian cancer.
Meiwu Technology Company Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wnw#NASDAQ">WNW</a>) shares were also up, gaining 78% to $0.1279.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Replimune Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/repl#NASDAQ">REPL</a>) shares dropped 51% to $6.00 after the company announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for the treatment of locally advanced or metastatic CSCC and provided initial data for all patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial.
Shares of iBio, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ibio#NYSE">IBIO</a>) were down 41% to $1.60 after the company announced pricing of a $4.5 million public offering.
Designer Brands Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dbi#NYSE">DBI</a>) was down, falling 31% to $8.84 after the company reported worse-than-expected third-quarter financial results and lowered FY23 adjusted EPS guidance.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36088456/top-5-tech-stocks-that-could-lead-to-your-biggest-gains-in-december"> Top 5 Tech Stocks That Could Lead To Your Biggest Gains In December</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.9% to $73.72 while gold traded up 0.1% at $2,043.60.
Silver traded down 0.6% to $24.77 on Tuesday while copper fell 0.8% to $3.8055.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.1%, London&rsquo;s FTSE 100 fell 0.5% while Spain&rsquo;s IBEX 35 Index rose 0.5% The German DAX rose 0.4% French CAC 40 rose 0.4%, while Italy&rsquo;s FTSE MIB Index rose 0.1%.
Industrial producer prices in the Eurozone fell by 9.4% year-over-year in October versus a 12.4% decline a month ago. The HCOB Eurozone services PMI was revised higher to 48.7 in November compared to a preliminary level of 48.2, and versus 47.8 in October.
The S&amp;P Global/CIPS UK services PMI was rose to 50.9 in November versus a preliminary reading of 50.5, while French services PMI came at 45.4 in November versus preliminary estimates of 45.3. German services PMI was revised higher to 49.6 in November versus a preliminary reading of 48.7.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly lower on Tuesday, with Japan&rsquo;s Nikkei 225 falling 1.37%, Hong Kong&rsquo;s Hang Seng Index falling 1.91% and China&rsquo;s Shanghai Composite Index falling 1.67%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, climbed 0.63%.
The S&amp;P Global India services PMI fell to 56.9 in November compared to prior month&rsquo;s reading of 58.4, while Caixin China General service PMI rose to 51.5 in November versus 50.4 a month ago. The au Jibun Bank Japan services PMI was revised lower to 50.8 in November compared to a preliminary reading of 51.7, while S&amp;P Global Hong Kong SAR PMI climbed to 50.1 in November compared to 48.9 a month ago. The Reserve Bank of Australia held its cash rates at 4.35% during its recent meeting.
&nbsp;
<h3>Economics</h3>
&nbsp;
The ISM services index will be released at 10:00 a.m. ET.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36088343/block-to-rally-around-54-here-are-10-top-analyst-forecasts-for-tuesday"> Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Tuesday</a>

US Stocks Down; JM Smucker Posts Upbeat Earnings

iBio shares are trading lower after the company announced pricing of a $4.5 million public offering.

Shares of GitLab Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gtlb#NASDAQ">GTLB</a>) rose sharply in pre-market trading after the company posted better-than-expected results for its third quarter and issued a <a href="https://www.benzinga.com/news/earnings/23/12/36080955/gitlab-stock-pops-after-q3-results-and-guidance-surpass-estimates-the-details">strong forecast for FY24</a>.
GitLab posted earnings of nine cents per share, exceeding the Street&#39;s estimate of losses of one cent per share. Quarterly sales of $149.70 million clocked in above analyst expectations of $141.49 million, according to <a href="http://pro.benzinga.com/">Benzinga Pro</a>.
The company said it sees full-year 2024 earnings to be between 12 cents and 13 cents per share, versus the estimate of losses of six cents. Full-year revenue is expected to be between $573 million and $574 million, versus the $558.14 million estimate.
GitLab shares gained 16.4% to $61.63 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Wheeler Real Estate Investment Trust Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/whlr#NASDAQ">WHLR</a>) shares gained 62.5% to $0.46 in pre-market trading after falling over 12% on Monday.</li>
<li>Meta Materials Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mmat#NASDAQ">MMAT</a>) shares rose 52.7% to $0.1068 in pre-market trading. Meta Materials shares fell 36% on Monday after the company announced a $6 million registered direct offering.</li>
<li>NeuroSense Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrsn#NASDAQ">NRSN</a>) rose 38.9% to $2.07 in pre-market trading. NeuroSense will report new data from randomized, placebo-controlled, double-blind segment of Phase 2b PARADIGM ALS trial on Dec. 5.</li>
<li>Sonoma Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snoa#NASDAQ">SNOA</a>) shares surged 37.8% to $0.2611 in pre-market trading after gaining 12% on Monday. The company, last month, posted weak quarterly results.</li>
<li>Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) gained 32.2% to $0.0361 in pre-market trading after gaining 29% on Monday.</li>
<li>Universal Security Instruments, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uuu#NYSE">UUU</a>) shares rose 14.2% to $2.49 in pre-market trading. Universal Security, last month, posted a loss for the second quarter.</li>
<li>Esports Entertainment Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmbl#NASDAQ">GMBL</a>) shares rose 13.4% to $0.0211 in pre-market trading.</li>
<li>Nexalin Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxl#NASDAQ">NXL</a>) gained 12.1% to $0.49 in pre-market trading.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ino#NASDAQ">INO</a>) shares climbed 11.4% to $0.4510 in pre-market trading. Inovio Pharmaceuticals, last month, posted in-line loss for the third quarter.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alterity Therapeutics Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athe#NASDAQ">ATHE</a>) dipped 21.2% to $3.31 in pre-market trading. Alterity Therapeutics will host webcast to discuss ATH434 efficacy data in primates and recent clinical progress on Tuesday, Dec. 5 in the US.</li>
<li>SilverSun Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssnt#NASDAQ">SSNT</a>) shares fell 21.1% to $9.86 in pre-market trading after jumping 240% on Monday. SilverSun Technologies announced Jacobs Private Equity II and minority co-investors will invest $1 billion in the company.</li>
<li>GRI Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gri#NASDAQ">GRI</a>) shares fell 17.7% to $0.6070 in pre-market trading. GRI Bio recently announced FDA clearance of IND for lead program GRI-0621, a Type 1 invariant NKT antagonist for the treatment of idiopathic pulmonary fibrosis.</li>
<li>Lucy Scientific Discovery Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lsdi#NASDAQ">LSDI</a>) shares fell 17.2% to $0.2830 in pre-market trading after gaining over 66% on Monday.</li>
<li>iBio, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ibio#NYSE">IBIO</a>) shares fell 15.2% to $2.29 in pre-market trading after declining 10% on Monday. iBio recently approved a 20-to-1 reverse stock split of its common stock.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrpx#NASDAQ">VRPX</a>) fell 14.5% to $0.38 in pre-market after surging 12% on Monday. Virpax Pharmaceuticals recently appointed Gerald Bruce as CEO and Eric Floyd as Chairman.</li>
<li>Minim, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) fell 13.2% to $3.30 in pre-market trading after jumping 19% on Monday.</li>
<li>Taoping Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/taop#NASDAQ">TAOP</a>) fell 12.8% to $1.42 in pre-market trading after gaining more than 10% on Monday.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) shares fell 11.6% to $0.7870 in pre-market trading after the company reported third-quarter earnings.</li>
<li>Sphere 3D Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/any#NASDAQ">ANY</a>) fell 9.3% to $0.9701 in pre-market trading after jumping over 33% on Monday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/12/36084953/jm-smucker-autozone-and-3-stocks-to-watch-heading-into-tuesday"> JM Smucker, AutoZone And 3 Stocks To Watch Heading Into Tuesday</a>

GMBL

LSDI

MINM

MMAT

SNOA

TAOP

WHLR

Why GitLab Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) shares rose 44.0% to $0.86 during Tuesday's pre-market session. The company's market cap stands at $3.9 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock rose 26.15% to $0.24. The company's market cap stands at $3.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock moved upwards by 23.54% to $4.04. The company's market cap stands at $130.3 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) stock moved upwards by 22.21% to $0.23. The market value of their outstanding shares is at $11.2 million. </li>
<li>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) shares rose 18.85% to $0.46. The company's market cap stands at $54.5 million. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) shares increased by 16.74% to $18.75. The company's market cap stands at $1.4 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock fell 52.4% to $5.87 during Tuesday's pre-market session. The company's market cap stands at $346.7 million. </li>
<li>iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) stock fell 40.0% to $1.62. The company's market cap stands at $2.2 million. </li>
<li>Science 37 Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCE#NASDAQ">SNCE</a>) stock declined by 19.8% to $0.2. The market value of their outstanding shares is at $23.9 million. </li>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) stock fell 19.6% to $0.28. The company's market cap stands at $4.8 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock fell 19.05% to $3.4. The company's market cap stands at $13.8 million. </li>
<li>DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) shares decreased by 18.75% to $1.3. The company's market cap stands at $35.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DRIO

DTIL

ONMD

SNCE

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), today announced the pricing of its reasonable best efforts public offering of 2,250,000 of its shares of common stock (or common stock equivalents in lieu thereof) and accompanying Series C and Series D warrants to purchase up to an aggregate of 2,250,000 shares of common stock at a combined public offering price of $2.00, resulting in gross proceeds of approximately $4.5 million. The Series C Warrants to purchase up to an aggregate of 2,250,000 shares of common stock and Series D Warrants to purchase up to an aggregate of 2,250,000 shares of common stock will have an exercise price of $2.00 per share, will be exercisable immediately following the date of issuance and will expire two years and five years from the original issuance date, respectively. &nbsp;
The closing of the offering is expected to occur on or about December 7, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, including for research and development and other trial preparation expenses and, retention and severance payments to certain of its employees or former employees. The Company may also use a portion of the net proceeds to invest in or acquire other products, businesses or technologies, although it has no commitments or agreements with respect to any such investments or acquisitions as of the date of this press release.
A.G.P./Alliance Global Partners&nbsp;is acting as the lead placement agent for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as co-placement agent for the offering.

iBio, Inc. Announces Pricing Of $4.5M Public Offering

Ibio Inc (IBIO) is up 15.48% today. IBIO has an Overall Score of 61. Find out what this means to you and get the rest of the rankings on IBIO!See Full IBIO ReportIBIO stock closed at $3.36 and is up $0.52 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors onl

Ibio Inc (IBIO) has risen 15.48% Thursday In Premarket Trading

iBio, Mesoblast, Kodiak Sciences among healthcare movers

Ibio Inc (IBIO) is down Monday morning, with the stock losing -8.87% in pre-market trading to 3.7. IBIO's short-term technical score of 73 indicates that the stock has traded more bullishly over the last month than 73% of stocks on the market. In the Biotechnology industry, which ranks 92 out of 146 industries, Ibio Inc ra

Ibio Inc (IBIO) has fallen 8.87% Monday In Premarket Trading

Ibio Inc (IBIO) has issued an announcement. iBio, Inc. secured approximately $15.1 million in a private placement deal with institutional and accre...

iBio Inc. Raises $15M in Private Placement and Issues Warrants

HUT, CXAI and BDRX among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The healthcare industry has historically provided significant returns to investors, with a predicted&nbsp;CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet. This is because many healthcare companies rely on trials that need to be approved by the Food and Drug Administration (FDA), making their performance difficult to predict.&nbsp;



Many companies, particularly small-cap companies, see massive share price declines when their trials fail or their treatments are not approved. Investors in the healthcare industry take great care as these risks make the industry a common target for short sellers. With that in mind, here are three <a href="https://investorplace.com/industries/healthcare/">healthcare stocks</a> short sellers are prescribing for trouble that investors should sell.



<h2>Healthcare Stocks Targeted by Short Sellers: Moderna (MRNA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/04/mrna1600-300x169.png" alt="Moderna logo is seen at the entrance to its headquarters in Cambridge, Massachusetts. Moderna, Inc., (MRNA) is an American pharmaceutical and biotechnology company."><div>Source: Tada Images / Shutterstock.com</div></div>Moderna (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrna-stock-quote/">MRNA</a>) is a pharmaceutical and biotechnology company headquartered in Cambridge, Massachusetts. The company focuses on producing medicines based on mRNA, and its stock has surged drastically after receiving government approval for an mRNA vaccine for Covid-19 during the pandemic. 



Moderna has experienced four days of consecutive losses after U.S. District Judge Mitchell Goldberg <a href="https://www.barrons.com/articles/moderna-stock-patent-covid-19-51638456764">ruled in favor</a> of Arbutus Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/abus-stock-quote/">ABUS</a>), a biotech company that is involved in a patent infringement lawsuit with Moderna related to the latter&rsquo;s Covid-19 vaccines. Shares of Moderna fell 4% on Wednesday following an unfavorable ruling against the company.



Over <a href="https://www.investopedia.com/how-moderna-makes-money-5179565#:~:text=Moderna%20Revenue%20Breakdown%3A%20Product%20sales,Collaboration%20revenue%2C%20a%20tiny%20fraction.&amp;text=&#x2A;%20Sales%20of%20Moderna's%20COVID%2D19,sales%20in%20Q4%20FY%202021.">95% of Moderna&rsquo;s revenue</a> is generated through its product sales. Various grants and subsidies from the government and private organizations make up the remaining 5%. Despite Moderna&rsquo;s massive success in recent years due to its development of mRNA Covid-19 vaccines, the company&rsquo;s recent loss in the lawsuit will make it a vulnerable target for short sellers.



Furthermore, Moderna&rsquo;s financials raise concerns for investors. In the fourth quarter of the 2023 fiscal year, Moderna experienced a drop of <a href="https://investorplace.com/2024/03/its-time-3-failing-biotech-stocks-to-sell-right-now/">45% in total revenue</a> and an 85% fall in net income year-over-year. Moderna remains highly dependent on revenues from vaccines. The company is also lacking experience in pharma sales compared to its larger competitors like Pfizer (NASDAQ:<a href="https://investorplace.com/stock-quotes/pfe-stock-quote/">PFE</a>). Combined with the lawsuit loss, the company&rsquo;s prognosis is grim. Until the company can improve its declining revenue patterns and offload the heavy reliance on vaccine sales by expanding into multiple revenue streams, Moderna stock remains a sell.



<h2>InnovAge (INNV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/innv1600-300x169.png" alt="InnovAge (INNV) offers comprehensive health care and support services to seniors. They strive to enable older adults to age independently at home."><div>Source: MacroEcon / Shutterstock.com</div></div>InnovAge Holding Corp (NASDAQ:<a href="https://investorplace.com/stock-quotes/innv-stock-quote/">INNV</a>) is a healthcare company based in Denver, Colorado, that provides medical and ancillary services for the elderly who are in need of care and support to live independently. The firm operates in the <a href="https://www.medicare.gov/health-drug-plans/health-plans/your-coverage-options/other-medicare-health-plans/PACE">system known as PACE</a> (Program of All-Inclusive Care for the Elderly), and about 150 of these PACE programs currently serve more than 70,000 patients across the nation. 



Recently, Goldman Sachs lowered its target price for InnovAge Holding from <a href="https://www.marketbeat.com/instant-alerts/nasdaq-innv-percent-advance-2024-04-01/">$8 to $7</a>, while JPMorgan Chase lowered its price target on shares from $7 to $6 in a research report published on Wednesday, March 13.



Moreover, the company&rsquo;s most recent reported balance sheet makes InnovAge a good target for short sellers. The company held <a href="https://simplywall.st/stocks/us/healthcare/nasdaq-innv/innovage-holding/news/innovage-holding-nasdaqinnv-has-debt-but-no-earnings-should">$123.1 million</a> in liabilities due within 12 months, along with an additional $108.2 million due after a year, while only holding $98.8 million in cash and $43.7 million worth of receivables. While its EPS has improved <a href="https://www.cnn.com/markets/stocks/INNV">64.82%</a> YoY, it remains negative at 0.03, and due to its overvaluation, investors should be cautious about InnovAge.



<h2>Healthcare Stocks Targeted by Short Sellers: iBio (IBIO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ibio1600-300x169.jpg" alt="A scientist in medical gear peers through a microscope. IBIO stock"><div>Source: Shutterstock</div></div>iBio (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ibio-stock-quote/">IBIO</a>) is an American pharmaceutical company that focuses on biotherapeutic drugs. The producer&rsquo;s leading drug candidates of note include iBio-400, which is a vaccine that treats classical swine fever, and iBio-101, an immuno-oncology drug that treats cancer. 



Yet, iBio is extremely far from a fully approved product that will generate a consistent profit. None of iBio&rsquo;s nine current drugs are currently in clinical trials, with most in the early discovery stage. The stock has <a href="https://finance.yahoo.com/quote/IBIO/">experienced a fall of 90%</a> in its price YoY, which may seem like a positive signal to buy. Although the company&rsquo;s net income in FY 2023 has improved from FY 2022, iBio is still losing money and is considered overvalued by several brokerages. Shares of iBio have fallen nearly 40% in the last five days, indicating it is getting heavily targeted by short sellers. 



Furthermore, because iBio lacks an innovative drug that will enter the market in the next couple of years, its stock does not showcase any promising signs of performing well in the short or long term. Therefore, investors should consider selling IBIO stock.&nbsp;



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>&nbsp;



On the date of publication, Andy Kim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Andy is a self-taught investor who is interested in ESG and socially responsible investing. He has managed the portfolio of a small investment fund and started his own research firm. Through his freelance writing on InvestorPlace, he hopes to find and share promising investments in companies with the goal of bettering the world.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/3-healthcare-stocks-short-sellers-are-prescribing-for-trouble/">3 Healthcare Stocks Short Sellers Are Prescribing for Trouble</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Healthcare Stocks Short Sellers Are Prescribing for Trouble

iBio files to sell 10.57M shares of common stock for holders

ABUS

ALLG

ARBK

BYSI

CRVO

CXAI

GRDI

IMNN

INNV

MRNA

MSTR

OCGN

PTPI

SERA

Press Releases

iBio Announces Reverse Stock Split

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Opinion

Thinking about buying stock in Mongodb, Aquestive Therapeutics, Sovos Brands, Travere Therapeutics, or Ibio Inc?

Financing

iBio Amends and Extends Maturity of Credit Agreement

iBio Announces Participation in 23rd Annual PepTalk Conference

Thinking about buying stock in Ibio Inc, Nokia, C4 Therapeutics, 1847 Holdings, or CleanSpark?

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

iBio Announces $15.0 Million Private Placement

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Thinking about buying stock in Ibio, Village Farms International, MariaDB, Nexgel, or Urban Outfitters ?

-

-

-

-

-

-

-

-

-

-

-

-

-

-

iBio Stock (AMEX:IBIO), Short Interest Report

People Also Watch